Lymphocyte Specific Neutra™ Antibody Products

Are prolonged drug development timelines or inconsistent lymphocyte-targeting antibody performance hindering your progress? Creative Biolabs' lymphocyte-specific Neutra™ antibody products leverage advanced hybridoma screening and recombinant protein engineering to deliver high-affinity, validated antibodies that streamline immune cell characterization, therapeutic validation, and diagnostic assay development.

Introduction to Lymphocyte

Lymphocytes, a heterogeneous group of white blood cells, are central to adaptive immunity and comprise B cells, T cells, and natural killer (NK) cells. These cells orchestrate antigen-specific responses, antibody production, and cytotoxic elimination of infected or malignant cells. Their dysregulation is implicated in autoimmune disorders, immunodeficiencies, and cancer, making them critical targets for therapeutic intervention.

• Structure

Lymphocytes are characterized by surface receptors dictating functional specificity.

- B cells express membrane-bound immunoglobulins (BCRs) for antigen recognition.

- T cells utilize T cell receptors (TCRs) complexed with CD3 subunits for antigen-MHC interaction.

- NK cells deploy activating/inhibitory receptors (e.g., CD16, NKG2D) to distinguish healthy from stressed cells.

Structural diversity arises from clonal receptor variation, enabling precise immune surveillance.

• Related Signaling Pathways

Lymphocyte activation hinges on tightly regulated pathways:

- TCR-CD3 Complex: Antigen binding triggers ZAP-70 recruitment, initiating MAPK/NF-κB cascades to drive proliferation and cytokine release.

- BCR Signaling: Antigen engagement activates SYK and BTK kinases, promoting B cell differentiation into antibody-secreting plasma cells.

- Checkpoint Pathways: PD-1/PD-L1 and CTLA-4 interactions modulate T cell exhaustion, a key focus in cancer immunotherapy.

Fig.1 Overview of TCR signaling cascades.¹

• Pathologies

Lymphocyte dysfunction underlies diverse conditions:

- Autoimmunity: Aberrant self-antigen recognition (e.g., rheumatoid arthritis, lupus) drives tissue damage.

- Immunodeficiency: Genetic defects (e.g., SCID) or infections (e.g., HIV) impair lymphocyte counts or function.

- Malignancies: Leukemias and lymphomas arise from uncontrolled lymphocyte proliferation.

Applications of Lymphocyte-Neutralizing Antibodies

• Therapeutic Intervention in Autoimmune Diseases

Neutralizing antibodies against B cell markers (e.g., CD20) or pro-inflammatory cytokines (e.g., TNF-α) reduce pathogenic autoantibodies and inflammation in rheumatoid arthritis and multiple sclerosis.

• Cancer Immunotherapy Development

Anti-PD-1/PD-L1 antibodies restore T cell cytotoxicity in tumors, while anti-CD19 CAR-T cell therapies target B cell malignancies with high precision.

• Organ Transplant Rejection Prevention

Antibodies targeting IL-2 receptors (e.g., CD25) or co-stimulatory molecules (e.g., CD28) suppress T cell activation, minimizing graft-versus-host disease.

• Infectious Disease Research

Neutralizing antibodies against HIV gp120 or SARS-CoV-2 spike protein block viral entry, informing vaccine design and passive immunization strategies.

• Diagnostic Assay Development

High-specificity antibodies enable quantification of lymphocyte subsets in patient blood, aiding in disease monitoring and treatment efficacy assessment.

Our Anti-Lymphocyte Antibodies

Creative Biolabs' lymphocyte-specific Neutra™ antibody products empower researchers and clinicians to dissect immune mechanisms and accelerate therapeutic innovation. Our rigorously validated antibodies, customizable for ELISA, flow cytometry, and functional assays, are trusted tools in oncology, autoimmunity, and infectious disease research. The lymphocyte-specific antibodies are engineered for unparalleled specificity and functional reproducibility.

- Surface Marker Detection: Anti-CD3, CD19, and CD56 antibodies enable precise subset isolation via flow cytometry or magnetic sorting.

- Functional Neutralization: Antibodies blocking PD-1, CTLA-4, or IL-2 receptors inhibit checkpoint signals or cytokine-driven activation, critical for immunotherapy development.

- In Vivo Depletion: Anti-CD20 (B cells) or anti-CD52 (pan-lymphocyte) antibodies facilitate mechanistic studies in preclinical models.

Validated across ELISA, immunohistochemistry, and live-cell imaging, these antibodies ensure reliability in research and translational applications.

Contact our scientific team today to explore tailored solutions for your lymphocyte-focused projects.

REFERENCE

1. Hwang, Jeong-Ryul, et al. "Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development." Experimental & molecular medicine 52.5 (2020): 750-761. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s12276-020-0435-8